P2X7 Receptor Antagonists Using Single Variable Domain Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to the P2X7 receptor, such as neurodegenerative disorders and inflammatory conditions, face challenges due to the lack of specificity in small molecule inhibitors, which often affect related or unrelated proteins, and the need for more effective therapeutic agents that can modulate P2X7 activity.
Innovation Solution
Development of polypeptides comprising immunoglobulin single variable domains that specifically bind to the P2X7 receptor, offering improved prophylactic, therapeutic, and diagnostic properties by modulating P2X7 activity with increased efficacy and specificity, including bivalent and bispecific designs that enhance binding affinity and detection sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to treat P2X7 receptor-related diseases, then therapeutic effects are achieved, but specificity is reduced and related or unrelated proteins are affected
Solution Approach 1:
The invention segments the antibody structure into single variable domains (SVDs) that specifically target the P2X7 receptor. By using minimal functional units (SVDs) rather than complete antibodies or small molecules, the patent achieves high specificity for P2X7 while avoiding off-target effects on unrelated proteins. The SVDs can be further segmented into bivalent or bispecific configurations to enhance specificity and therapeutic effect.
Solution Approach 2:
The invention changes the molecular parameter from small molecule inhibitors to polypeptide-based single variable domains. This parameter change fundamentally alters the interaction mechanism with the P2X7 receptor, providing superior specificity and binding affinity while maintaining therapeutic efficacy. The polypeptide structure allows for precise epitope recognition that small molecules cannot achieve.
2Reliability
If polypeptides with high specificity for P2X7 are developed, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The invention extracts only the essential functional component (single variable domain) from the complete antibody structure. This extraction simplifies the manufacturing process compared to producing full-length antibodies, while maintaining the high specificity required for P2X7 targeting. The SVD can be produced as a standalone polypeptide with reduced structural complexity.
Solution Approach 2:
The single variable domain serves multiple functions: it provides high specificity binding to P2X7, can be configured in bivalent or bispecific formats for enhanced efficacy, and maintains stability for therapeutic use. This multi-functionality in a single structural unit reduces overall system complexity while achieving multiple therapeutic goals.
3Measurement precision
If bivalent and bisspecific polypeptide designs are used, then binding affinity and detection sensitivity are enhanced, but structural complexity increases
Solution Approach 1:
The invention merges two or more single variable domains into a single polypeptide chain to create bivalent or bispecific configurations. This merging approach enhances binding affinity and detection sensitivity through multivalent binding, while the modular design keeps the structural complexity manageable compared to traditional multivalent antibodies.
Solution Approach 2:
The polypeptide structure combines multiple functional domains (SVDs) into a composite molecular architecture. This composite structure integrates high-affinity binding sites with appropriate spacing and orientation, achieving enhanced detection sensitivity and binding affinity while maintaining a relatively simple overall structure that is more manageable than conventional antibody formats.
Data Source
AI summary
The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.